Johnson & Johnson $JNJ Shares Bought by Rockline Wealth Management LLC

Rockline Wealth Management LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,504 shares of the company’s stock after purchasing an additional 400 shares during the quarter. Johnson & Johnson accounts for 1.1% of Rockline Wealth Management LLC’s investment portfolio, making the stock its 27th largest position. Rockline Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,812,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth approximately $35,000. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the 1st quarter worth $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.4%

NYSE:JNJ opened at $186.24 on Tuesday. The stock’s fifty day moving average price is $183.43 and its two-hundred day moving average price is $167.96. The company has a market cap of $448.71 billion, a price-to-earnings ratio of 17.98, a P/E/G ratio of 2.19 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. HSBC upped their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Loop Capital set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 22nd. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.